Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG4716 DDI Study with Nintedanib and Pirfenidone
NCT04971746Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Jul 2021
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of OATD-01 in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Galapagos NV. Primary endpoints: Maximum observed plasma concentration of pirfenidone, Area under the plasma concentration-time curve from time zero to infinity of pirfenidone and 2 more. Started Jul 2021; status: completed.
02
Drugs
OATD-01
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04971746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971746.